What is Biosensia?
Biosensia operates at the intersection of biotechnology and clinical diagnostics, specializing in advanced biomarker testing. The company provides proprietary systems designed to deliver real-time, precise information on complement proteins and other critical biological markers. By offering comprehensive services that include assay development and custom panel creation, Biosensia serves a diverse clientele ranging from clinical laboratories to healthcare practitioners. Their market position is defined by a rigorous adherence to regulatory standards and a focus on translating intricate immune data into tangible therapeutic benefits, thereby enhancing the standard of care for patients globally.
How much funding has Biosensia raised?
Biosensia has raised a total of $4.6M across 2 funding rounds:
Private Equity
$2.9M
Private Equity
$1.7M
Private Equity (2008): $2.9M with participation from Atlantic Bridge Capital, Enterprise Ireland, Seroba BioVentures, and Street Capital
Private Equity (2011): $1.7M led by Atlantic Bridge Capital, Act Venture Capital, and Seroba BioVentures
Key Investors in Biosensia
Atlantic Bridge Capital
A growth technology fund that targets cross-border companies operating in core sectors such as software, cloud, and advanced technology.
Seroba BioVentures
A European life sciences venture capital firm focused on investing in high-potential innovations within the biotech and medtech sectors.
Enterprise Ireland
A government agency dedicated to the development and international growth of Irish businesses across manufacturing and service industries.
What's next for Biosensia?
With the support of its institutional backers, Biosensia is poised to expand its footprint in the diagnostic sector. The current funding context suggests a strategic pivot toward broader market adoption of its proprietary platforms. Future initiatives will likely focus on scaling assay production, deepening partnerships with clinical research organizations, and refining its diagnostic panels to address emerging therapeutic needs. As the company matures, the focus will remain on maintaining its technological edge in biomarker testing while navigating the complexities of global healthcare regulatory environments to ensure long-term commercial viability and clinical impact.
See full Biosensia company page
